Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domain

Shirish Shukla; Weijiang Ying; Felicia Gray; Yiwu Yao; Miranda L. Simes; Qingjie Zhao; Hongzhi Miao; Hyo Je Cho; Paula González-Alonso; Alyssa Winkler; George Lund; Trupta Purohit; EunGi Kim; Xiaotian Zhang; Joshua M. Ray; Shihan He; Caroline Nikolaidis; Juliano Ndoj; Jingya Wang; Lukasz Jaremko; Mariusz Jaremko; Russell J. H. Ryan; Monica L. Guzman; Jolanta Grembecka; Tomasz Cierpicki

doi:10.1038/s41589-021-00815-5

Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domain

Shirish Shukla, Weijiang Ying, Felicia Gray, Yiwu Yao, Miranda L. Simes, Qingjie Zhao, Hongzhi Miao, Hyo Je Cho, Paula González-Alonso, Alyssa Winkler, George Lund, Trupta Purohit, EunGi Kim, Xiaotian Zhang, Joshua M. Ray, Shihan He, Caroline Nikolaidis, Juliano Ndoj, Jingya Wang, Lukasz JaremkoMariusz Jaremko, Russell J. H. Ryan, Monica L. Guzman, Jolanta Grembecka, Tomasz Cierpicki

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

Polycomb repressive complex 1 (PRC1) is an essential chromatin-modifying complex that monoubiquitinates histone H2A and is involved in maintaining the repressed chromatin state. Emerging evidence suggests PRC1 activity in various cancers, rationalizing the need for small-molecule inhibitors with well-defined mechanisms of action. Here, we describe the development of compounds that directly bind to RING1B–BMI1, the heterodimeric complex constituting the E3 ligase activity of PRC1. These compounds block the association of RING1B–BMI1 with chromatin and inhibit H2A ubiquitination. Structural studies demonstrate that these inhibitors bind to RING1B by inducing the formation of a hydrophobic pocket in the RING domain. Our PRC1 inhibitor, RB-3, decreases the global level of H2A ubiquitination and induces differentiation in leukemia cell lines and primary acute myeloid leukemia (AML) samples. In summary, we demonstrate that targeting the PRC1 RING domain with small molecules is feasible, and RB-3 represents a valuable chemical tool to study PRC1 biology.

Original language	English (US)
Journal	Nature Chemical Biology
DOIs	https://doi.org/10.1038/s41589-021-00815-5
State	Published - Jun 21 2021

Bibliographical note

KAUST Repository Item: Exported on 2021-06-23
Acknowledgements: This work was funded by the National Institute of Health (NIH) R01 grants CA207272, CA226759 and CA240514 to T.C., CA201204, CA244254 and CA160467 to J.G. and LLS Scholar grants (1340-17) to T.C. and (1215-14) to J.G. This research used resources of the Advanced Photon Source, a US Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under contract number DE-AC02-06CH11357. Use of the LS-CAT Sector 21 was supported by the Michigan Economic Development Corporation and the Michigan Technology Tri-Corridor (grant 085P1000817). TEX and MLL–ENL cells were received from J. Dick, University Health Network, Toronto, Canada. We thank M. Carroll and G. Danet-Desnoyers from the Stem Cell and Xenograft Core at the University of Pennsylvania for providing a human AML primary sample.

ASJC Scopus subject areas

Cell Biology
Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41589-021-00815-5

https://repository.kaust.edu.sa/bitstream/10754/669743/1/Cierpicki_PRC1_NCB2021%20%282%29.pdf

Cite this

Shukla, S., Ying, W., Gray, F., Yao, Y., Simes, M. L., Zhao, Q., Miao, H., Cho, H. J., González-Alonso, P., Winkler, A., Lund, G., Purohit, T., Kim, E., Zhang, X., Ray, J. M., He, S., Nikolaidis, C., Ndoj, J., Wang, J., ... Cierpicki, T. (2021). Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domain. Nature Chemical Biology. https://doi.org/10.1038/s41589-021-00815-5

@article{e65ef4a9c9b740889f3729ef9d6211c4,

title = "Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domain",

abstract = "Polycomb repressive complex 1 (PRC1) is an essential chromatin-modifying complex that monoubiquitinates histone H2A and is involved in maintaining the repressed chromatin state. Emerging evidence suggests PRC1 activity in various cancers, rationalizing the need for small-molecule inhibitors with well-defined mechanisms of action. Here, we describe the development of compounds that directly bind to RING1B–BMI1, the heterodimeric complex constituting the E3 ligase activity of PRC1. These compounds block the association of RING1B–BMI1 with chromatin and inhibit H2A ubiquitination. Structural studies demonstrate that these inhibitors bind to RING1B by inducing the formation of a hydrophobic pocket in the RING domain. Our PRC1 inhibitor, RB-3, decreases the global level of H2A ubiquitination and induces differentiation in leukemia cell lines and primary acute myeloid leukemia (AML) samples. In summary, we demonstrate that targeting the PRC1 RING domain with small molecules is feasible, and RB-3 represents a valuable chemical tool to study PRC1 biology.",

author = "Shirish Shukla and Weijiang Ying and Felicia Gray and Yiwu Yao and Simes, {Miranda L.} and Qingjie Zhao and Hongzhi Miao and Cho, {Hyo Je} and Paula Gonz{\'a}lez-Alonso and Alyssa Winkler and George Lund and Trupta Purohit and EunGi Kim and Xiaotian Zhang and Ray, {Joshua M.} and Shihan He and Caroline Nikolaidis and Juliano Ndoj and Jingya Wang and Lukasz Jaremko and Mariusz Jaremko and Ryan, {Russell J. H.} and Guzman, {Monica L.} and Jolanta Grembecka and Tomasz Cierpicki",

note = "KAUST Repository Item: Exported on 2021-06-23 Acknowledgements: This work was funded by the National Institute of Health (NIH) R01 grants CA207272, CA226759 and CA240514 to T.C., CA201204, CA244254 and CA160467 to J.G. and LLS Scholar grants (1340-17) to T.C. and (1215-14) to J.G. This research used resources of the Advanced Photon Source, a US Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under contract number DE-AC02-06CH11357. Use of the LS-CAT Sector 21 was supported by the Michigan Economic Development Corporation and the Michigan Technology Tri-Corridor (grant 085P1000817). TEX and MLL–ENL cells were received from J. Dick, University Health Network, Toronto, Canada. We thank M. Carroll and G. Danet-Desnoyers from the Stem Cell and Xenograft Core at the University of Pennsylvania for providing a human AML primary sample.",

year = "2021",

month = jun,

day = "21",

doi = "10.1038/s41589-021-00815-5",

language = "English (US)",

journal = "Nature Chemical Biology",

issn = "1552-4450",

publisher = "Nature Publishing Group",

}

Shukla, S, Ying, W, Gray, F, Yao, Y, Simes, ML, Zhao, Q, Miao, H, Cho, HJ, González-Alonso, P, Winkler, A, Lund, G, Purohit, T, Kim, E, Zhang, X, Ray, JM, He, S, Nikolaidis, C, Ndoj, J, Wang, J, Jaremko, L , Jaremko, M, Ryan, RJH, Guzman, ML, Grembecka, J & Cierpicki, T 2021, 'Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domain', Nature Chemical Biology. https://doi.org/10.1038/s41589-021-00815-5

TY - JOUR

T1 - Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domain

AU - Shukla, Shirish

AU - Ying, Weijiang

AU - Gray, Felicia

AU - Yao, Yiwu

AU - Simes, Miranda L.

AU - Zhao, Qingjie

AU - Miao, Hongzhi

AU - Cho, Hyo Je

AU - González-Alonso, Paula

AU - Winkler, Alyssa

AU - Lund, George

AU - Purohit, Trupta

AU - Kim, EunGi

AU - Zhang, Xiaotian

AU - Ray, Joshua M.

AU - He, Shihan

AU - Nikolaidis, Caroline

AU - Ndoj, Juliano

AU - Wang, Jingya

AU - Jaremko, Lukasz

AU - Jaremko, Mariusz

AU - Ryan, Russell J. H.

AU - Guzman, Monica L.

AU - Grembecka, Jolanta

AU - Cierpicki, Tomasz

N1 - KAUST Repository Item: Exported on 2021-06-23 Acknowledgements: This work was funded by the National Institute of Health (NIH) R01 grants CA207272, CA226759 and CA240514 to T.C., CA201204, CA244254 and CA160467 to J.G. and LLS Scholar grants (1340-17) to T.C. and (1215-14) to J.G. This research used resources of the Advanced Photon Source, a US Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under contract number DE-AC02-06CH11357. Use of the LS-CAT Sector 21 was supported by the Michigan Economic Development Corporation and the Michigan Technology Tri-Corridor (grant 085P1000817). TEX and MLL–ENL cells were received from J. Dick, University Health Network, Toronto, Canada. We thank M. Carroll and G. Danet-Desnoyers from the Stem Cell and Xenograft Core at the University of Pennsylvania for providing a human AML primary sample.

PY - 2021/6/21

Y1 - 2021/6/21

N2 - Polycomb repressive complex 1 (PRC1) is an essential chromatin-modifying complex that monoubiquitinates histone H2A and is involved in maintaining the repressed chromatin state. Emerging evidence suggests PRC1 activity in various cancers, rationalizing the need for small-molecule inhibitors with well-defined mechanisms of action. Here, we describe the development of compounds that directly bind to RING1B–BMI1, the heterodimeric complex constituting the E3 ligase activity of PRC1. These compounds block the association of RING1B–BMI1 with chromatin and inhibit H2A ubiquitination. Structural studies demonstrate that these inhibitors bind to RING1B by inducing the formation of a hydrophobic pocket in the RING domain. Our PRC1 inhibitor, RB-3, decreases the global level of H2A ubiquitination and induces differentiation in leukemia cell lines and primary acute myeloid leukemia (AML) samples. In summary, we demonstrate that targeting the PRC1 RING domain with small molecules is feasible, and RB-3 represents a valuable chemical tool to study PRC1 biology.

AB - Polycomb repressive complex 1 (PRC1) is an essential chromatin-modifying complex that monoubiquitinates histone H2A and is involved in maintaining the repressed chromatin state. Emerging evidence suggests PRC1 activity in various cancers, rationalizing the need for small-molecule inhibitors with well-defined mechanisms of action. Here, we describe the development of compounds that directly bind to RING1B–BMI1, the heterodimeric complex constituting the E3 ligase activity of PRC1. These compounds block the association of RING1B–BMI1 with chromatin and inhibit H2A ubiquitination. Structural studies demonstrate that these inhibitors bind to RING1B by inducing the formation of a hydrophobic pocket in the RING domain. Our PRC1 inhibitor, RB-3, decreases the global level of H2A ubiquitination and induces differentiation in leukemia cell lines and primary acute myeloid leukemia (AML) samples. In summary, we demonstrate that targeting the PRC1 RING domain with small molecules is feasible, and RB-3 represents a valuable chemical tool to study PRC1 biology.

UR - http://hdl.handle.net/10754/669743

UR - http://www.nature.com/articles/s41589-021-00815-5

U2 - 10.1038/s41589-021-00815-5

DO - 10.1038/s41589-021-00815-5

M3 - Article

C2 - 34155404

SN - 1552-4450

JO - Nature Chemical Biology

JF - Nature Chemical Biology

ER -

Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domain

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this